Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cibisatamab in CEA+ Solid Tumors
NCT02324257Phase 1Completed
- Sponsor
- Roche
- Start
- Dec 2014
- Primary completion
- Sep 2019
- Modality
- Bispecific Antibodies, Recombinant Proteins and Enzymes
- Countries
- 7
01
Overview
Phase 1, open-label trial of cibisatamab in solid tumor, colorectal cancer (CRC), pancreatic cancer (PC) and 3 more (2 arms), sponsored by Roche. Primary endpoints: Percentage of Participants with Adverse Events or Serious Adverse Events at 60 months, Percentage of Participants with Dose-Limiting Toxicities at 21 days and 4 more. Started Dec 2014; status: completed.
02
Drugs
cibisatamab
03
Conditions
solid tumorcolorectal cancer (CRC)pancreatic cancer (PC)gastric cancer (GC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02324257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02324257.